Four major studies presented at the Annual Meeting of the American Society of Hematology (ASH) (Orlando, December 6, 2025) have radically changed current approaches to managing blood disorders. The research topics covered a wide spectrum: anemia during pregnancy, management of infectious processes, survival rates for leukemia patients, and the financial burden of managing oncological diseases.
Safety of Intravenous Iron Amidst Infections
For decades, clinicians refrained from using intravenous (IV) iron in patients with acute bacterial infections. This approach was based on the hypothesis that free iron might enhance bacterial growth (promote proliferation) and exacerbate the course of the disease. Despite laboratory (in vitro) indications, clear clinical evidence based on human data was lacking.
The study relied on a large-scale analysis of data from over 85,000 hospitalized patients in the U.S. (2000–2024). Patients had iron-deficiency anemia and common infections such as: pneumonia (27,000+), urinary tract infections (UTIs, 23,000+), MRSA infections (15,000+), cellulitis (13,000+), colitis (7,000+), and meningitis (143).
IV iron treatment significantly improved clinical outcomes: In the vast majority of infections, a sharp reduction in mortality was recorded in both early (-day) and long-term (-day) periods.
The most impressive results were noted during severe infections such as: pneumonia, MRSA (Methicillin-Resistant Staphylococcus Aureus) sepsis, and colitis.
IV iron not only reduced mortality but also improved hemoglobin levels, even more so than in the control group.
The length of hospitalization increased by only hours, which is a clinically insignificant side effect.
Results were neutral in meningitis patients (due to the small sample size). Although this is an observational study and cannot prove a direct cause-and-effect relationship, its findings should prompt a re-evaluation of current clinical guidelines. Randomized controlled trials (RCTs) are essential for the final validation of these conclusions.
Iron Deficiency During Pregnancy
The physiological demand for iron sharply increases during pregnancy. Iron deficiency increases the risk of serious complications such as premature birth, low birth weight, and neurocognitive developmental delay. However, routine screening is often unsystematic and limited to detecting only anemia (hemoglobin ).
The innovative project by the Mayo Clinic standardized ferritin level testing at and weeks of gestation. The therapeutic strategy involved prescribing oral iron in cases of early deficiency and later using intravenous (IV) iron dextran.
One-year data showed:
The screening rate increased from 10% to 63%.
Two-thirds of the participants were confirmed to have iron deficiency.
The number of IV infusions increased 20-fold (to 21%).
Consequently, the overall hemoglobin level significantly improved, from to ; in non-anemic patients, it increased from to .
Against the backdrop of this improvement, the need for blood transfusions slightly decreased, from to .
This data demonstrates that implementing simple, standardized screening effectively prevents anemia and improves maternal and fetal health parameters.
Inequity in Leukemia Management
An analysis of large-scale studies conducted by the National Cancer Institute (NCI) from revealed a sharp inequity in clinical outcomes for Black patients with AML (Acute Myeloid Leukemia) (184 subjects) compared to White patients (3,469 subjects):
Age at Diagnosis: Black patients received a diagnosis an average of years earlier.
Mortality Risk: They had a 31% higher risk of leukemia-related fatal outcomes and a 21% higher overall mortality.
Prognosis (NPM1 Mutation): The survival rate for Black patients with the NPM1 mutation was almost half (months vs. months), despite the molecular profile of the disease (spectrum of mutations) being similar.
Access to Treatment: Black patients were less likely to undergo donor stem cell transplantation ( vs. ).
This data shows that even a biologically similar disease is prognosed differently based on racial background, indicating deep-seated structural flaws in the healthcare system.
Pediatric Leukemia (ALL) and Socioeconomic Burden
The diagnosis of Pediatric Acute Lymphoblastic Leukemia (ALL) is associated with a severe financial burden for families. A study of data from 422 families revealed a critical level of “financial toxicity”:
Basic Living Needs: 30% of families struggled to cover housing, food, and utility bills.
Income Reduction: Within 24 months of starting treatment, 31.5% of families lost 25% or more of their income.
New Financial Difficulties: 24% of families, who were considered financially stable before starting treatment, subsequently encountered new obstacles related to payments.
Social Risk Groups: The highest probability of financial hardship was found in Latino/Black families, low-income households, single-parent families, and users of state medical insurance (Medicaid).
As the moderator of the American Society of Hematology (ASH), Dr. Adam Cuker, noted: “Studies focused on re-evaluating clinical practice bring direct and real benefits to the patient population.” Accordingly, based on this data, official changes to clinical guidelines, intensive efforts to ensure equity, and a significant improvement in the quality of life for millions of patients are expected.
Source: American Society of Hematology
